Efficacy of Ceftriaxone or Meropenem as Initial Therapies in Whipple's Disease

 This article has an accompanying continuing medical education activity on page e11. Learning Objective: Upon completion of reading this article, successful learners will be able to define the primary diagnostic procedures to diagnose Whipple's disease and will to be able to specify the circumstances in a puzzling illness in which it is not necessary to consider Whipple's disease. The learner should further be able to select the most appropriate procedure to diagnose cerebral Whipple's disease and to define to-days evidence-based strategy in the treatment of Whipple's disease.

 Conflicts of interest The authors disclose no conflicts.

 Funding This work was supported by the Fifth Framework Program of the European Union (QLG1-CT-2002-01049). Dr Feurle was supported by the European Commission and has received an honorarium for a written expert opinion from Roche Pharma AG, Grenzach–Wyhlen, the producer of Ceftriaxone. Roche has never been in contact with Dr Feurle concerning the randomized trial. Drs Junga and Marth have received support from the European Commission.

PII: S0016-5085(09)01938-6

doi:10.1053/j.gastro.2009.10.041

© 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.